Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 4 institutions in 1 country.
Diana Trujillo-BenítezDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
Myrna Luna-GutiérrezDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-4082-3816
José G Aguirre-De PazDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
Pedro Cruz-NovaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0001-5719-7324
Gerardo Bravo-VillegasFaculty of Chemistry, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.
Joel E Vargas-AhumadaNuclear Medicine Department, Instituto Nacional de Cardiología, Mexico City 14000, Mexico.ORCID 0009-0003-9057-6109
Paola Vallejo-ArmentaNuclear Medicine Department, Instituto Nacional de Cancerología, Mexico City 14000, Mexico.ORCID 0000-0002-8260-913X
Enrique Morales-AvilaFaculty of Chemistry, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.ORCID 0000-0001-8471-6791
Nallely Jiménez-MancillaCátedras, CONACyT, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0001-9480-4621
Rigoberto Oros-PantojaFaculty of Medicine, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.ORCID 0000-0001-5441-0863
Clara Santos-CuevasDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0001-5903-1598
Erika Azorín-VegaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-7520-461X
Blanca Ocampo-GarcíaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-5831-8412
Guillermina Ferro-FloresDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0003-0296-7605
Instituto Nacional de Investigaciones Nucleares · MXUniversidad Autónoma del Estado de México · MXInstituto Nacional de Cancerología · MXInstituto Nacional de Cardiología · MX
Funding
Consejo Mexiquense de Ciencia y Tecnología FICDTEM-2021-008
6 · The paper itself
Abstract
Recently, we reported a new fibroblast activation protein (FAP) inhibitor radiopharmaceutical based on the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.